{"transactions":[{"id":732342,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":36864,"kind":"person","name":"Xavier Ramnik","position":1,"cik":"0001920780","reported_name":"Xavier Ramnik","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Buy","published_at":"2026-06-18T22:45:03.000Z","date":"2026-06-17","kind":"grant","planned":false,"acquired":true,"shares":22195,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 22,195 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 17, 2027 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":22195,"derivative":{"exercise_price":19.19,"expiration_date":"2036-06-17","underlying":"Class A ordinary shares, par value $0.0001 per share","underlying_shares":22195},"source":{"system":"sec-edgar","filing":"0001213900-26-070255","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920780/000121390026070255/ownership.xml","form_type":"4"}},{"id":1118245,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":36864,"kind":"person","name":"Xavier Ramnik","position":1,"cik":"0001920780","reported_name":"Xavier Ramnik","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Buy","published_at":"2025-06-09T13:07:15.000Z","date":"2025-06-05","kind":"grant","planned":false,"acquired":true,"shares":6682,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 6,682 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 5, 2026 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":6682,"derivative":{"exercise_price":48.83,"expiration_date":"2035-06-05","underlying":"Class A ordinary shares, par value $0.0001 per share","underlying_shares":6682},"source":{"system":"sec-edgar","filing":"0001213900-25-052367","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920780/000121390025052367/ownership.xml","form_type":"4"}},{"id":1487177,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":36864,"kind":"person","name":"Xavier Ramnik","position":1,"cik":"0001920780","reported_name":"Xavier Ramnik","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Buy","published_at":"2024-06-07T21:00:02.000Z","date":"2024-06-06","kind":"grant","planned":false,"acquired":true,"shares":7688,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 7,688 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 6, 2025, (ii) the date of the Issuer's next annual general meeting of shareholders and (iii) the date of a Change in Control (as defined in the MoonLake Immunotherapeutics 2022 Equity Incentive Plan) of the Issuer, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":7688,"derivative":{"exercise_price":42.44,"expiration_date":"2034-06-06","underlying":"Class A ordinary shares, par value $0.0001 per share","underlying_shares":7688},"source":{"system":"sec-edgar","filing":"0001213900-24-050828","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920780/000121390024050828/ownership.xml","form_type":"4"}},{"id":1859158,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":36864,"kind":"person","name":"Xavier Ramnik","position":1,"cik":"0001920780","reported_name":"Xavier Ramnik","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Buy","published_at":"2023-06-12T20:55:22.000Z","date":"2023-06-08","kind":"grant","planned":false,"acquired":true,"shares":11297,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"This option represents a right to purchase a total of 11,297 Class A Ordinary Shares of the Issuer, which will vest in full the earlier of (i) June 8, 2024 and (ii) the date of the Issuer's next annual general meeting of shareholders, subject to the Reporting Person's continued service to the Issuer."}],"balance_after":11297,"derivative":{"exercise_price":29.18,"expiration_date":"2033-06-08","underlying":"Class A ordinary shares, par value $0.0001 per share","underlying_shares":11297},"source":{"system":"sec-edgar","filing":"0001213900-23-048203","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920780/000121390023048203/ownership.xml","form_type":"4"}},{"id":2281016,"issuer":{"id":4785,"kind":"organization","name":"MoonLake Immunotherapeutics"},"owners":[{"id":36864,"kind":"person","name":"Xavier Ramnik","position":1,"cik":"0001920780","reported_name":"Xavier Ramnik","relationship":{"director":true,"officer":false,"ten_percent_owner":false,"other":false}}],"security":"Option to Buy","published_at":"2022-05-05T21:49:11.000Z","date":"2022-04-06","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Dr. Xavier was granted 45,000 options on April 6, 2022 pursuant to the MoonLake Immunotherapeutics 2022 Equity Incentive Plan (the \"Plan\"), vesting one-third on each of April 6, 2023, April 6, 2024 and April 6, 2025, in each case, subject to the terms of the Plan. Each option represents the right to acquire one Class A ordinary share, par value $0.0001 per share, of the Issuer."}],"balance_after":45000,"derivative":{"exercise_price":12.25,"expiration_date":"2032-04-06","underlying":"Class A ordinary shares, par value $0.0001 per share","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0001213900-22-024305","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920780/000121390022024305/ownership.xml","form_type":"4"}}]}